KCNJ8: ATP-sensitive inward rectifier potassium channel 8
Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on KCNJ8, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Diazoxide | Approved | Merck & Co. (MSD) | Small molecule | OpenerPotassium channel, inwardly rectifying, subfamily J, member 8 opener | 5 |
| Diazoxide in the Treatment of Type 1 Glycogenosis | Diazoxide | — | Not yet recruiting | Central Hospital, Nancy, France | Jul 31, 2026 |
| Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome | Diazoxide | — | Enrolling by invitation | Soleno Therapeutics, Inc. | Mar 5, 2026 |
| Effect of Insulin Lowering on Lipogenesis | Diazoxide | Phase 1 | Recruiting | Columbia University | Feb 11, 2026 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | Diazoxide | — | Recruiting | Duke University | Feb 20, 2020 |
| Regulation of Endogenous Glucose Production by Central KATP Channels | Diazoxide | Phase 2 | Recruiting | Albert Einstein College of Medicine | May 30, 2018 |
- Hypertrichotic osteochondrodysplasia Cantu type0.63
- Sudden infant death syndrome0.58
- Hypoglycemia0.48
- Hypertensive disorder0.47
- Hyperinsulinism0.44
- Hyperinsulinemic hypoglycemia0.37
- Pancreatic insulinoma0.37
- Obesity disorder0.29
- Cardiac arrhythmia0.21
- Brugada syndrome0.21
- Abnormality of the cardiovascular system0.19
- Congenital isolated hyperinsulinism0.18
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4770, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q15842, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets